Kornimate/medical-research-clean huggingface dataset:
cell selection for bone marrow transplants to prevent graft-versus-host-disease

Conditions: Graft vs Host Disease; Hematologic Neoplasm

Summary: blood contains different kinds of cells, white blood cells, red blood cells, and platelets. in order to treat certain diseases, specific cell types can be removed from blood and transplanted into patients. the process of removing white blood cells for the treatment of leukemia is called apheresis. this study will make available blood cell collections from volunteers genetically matched to various degrees with recipients in order to test and, if necessary, refine the process of removing white blood cell t-lymphocytes....

this protocol has been written to make available apheresis collections from volunteers matched to various degrees with recipients in order to test and, if necessary refine, the selective immunodepletion procedure prior to introducing it in a clinical trial.

Eligibility criteria:
* inclusion criteria: family members of patients admitted to nhlbi allogeneic bmt protocols. ages 18 and older and less than age 65. parent of patient (obligate haplotype match) or hla 3/6, 4/6, 5/6, or 6/6 match with patient. research apheresis available from patient. exclusion criteria: pregnancy or lactation. hla type unknown. more than one haplotype mismatch with patient. history of any immunosuppressive disease. history of chronic viral antigenic stimulus. venous access inadequate.

Keywords: volunteer leukocyte donors family members leukocyte collection no reimbursement
brisk walking training compared with cognitive behavioral therapy for the treatment of chronic primary insomnia in people aged 60 years or above: a randomized, partially blinded, non-inferiority trial

Conditions: Primary Insomnia

Summary: this study is a single-blinded (outcome assessor) and parallel-group non-inferiority rct. chinese older adults aged ≥60 years with chronic primary insomnia will be randomized evenly (1:1) to either the brisk walking training group or the cbt-i group. participants in the brisk walking training group receive an eight-week instructor-led interval brisk walking training (40 minutes/session, three sessions/week). participants in the cbt-i group receive standard-of-care group-based eight-session cbt-i (one session/week). self-reported and objective sleep outcomes are measured at baseline (t0), after completion of the intervention (t1), and six (t2), and 12 months after t1 (t3).


Eligibility criteria:
inclusion criteria: 1. aged ≥60 years; 2. ethnic chinese; able to read, write and speak cantonese 3. having a hong kong id; 4. willing to wear an accelerometer on the wrist for a week to assess sleep parameters at t0, t1, and t2. 5. score ≥10 in the insomnia severity index (isi) (presence of insomnia) 6. experiencing any one of the following symptoms for ≥3 days per week 1. difficulty initiating sleep; or 2. difficulty maintaining sleep; or 3. early-morning awakening with inability to return to sleep exclusion criteria: 1. score ≥1 in the chinese version of the physical activity readiness questionnaire (par-q); 2. currently regularly practicing a moderate-intensity pa program such as brisk walking or tai chi (≥3 times a week, ≥30 minutes/session); 3. currently receiving or scheduled to receive cbt-i during the study period; 4. score ≤16 in the validated telephone version of the cantonese mini-mental state examination (t-cmmse). 5. working nightshifts and unable/unwilling to discontinue such work pattern; 6. having a diagnosis of a major depressive disorder, anxiety disorders or other severe mental disorder (bipolar disorders, psychosis). those with mild depression or anxiety disorders will not be excluded; 7. use of antidepressant or antipsychotic medication or under treatment of other serious diseases (e.g., cancer chemotherapy) known to affect sleep; 8. presence of any serious chronic diseases which affect sleep (e.g., cancer, autoimmune diseases). 9. having a serious somatic condition preventing the participation of brisk walking training/cbt-i.
a study of 141w94 in combination with other anti-hiv drugs

Conditions: HIV Infections

Summary: to determine the steady-state pharmacokinetics of 141w94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. to determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141w94 after multiple oral dosing. to assess the safety and tolerability of multiple doses of 141w94 when combined with saquinavir, indinavir and nelfinavir.

patients will be randomized to receive open label 141w94 in combination with saquinavir, indinavir and nelfinavir. the randomized phase will be preceded by a single dose pharmacokinetic interaction study of 141w94 and indinavir in 12 patients. data from this single dose investigation will be used to determine the dose of indinavir to be used in the randomized phase.

Eligibility criteria:
inclusion criteria concurrent medication: allowed provided used with caution: medications that may interact at cyp3a4 (either a substrate, inhibitor or inducer of the enzyme) should be used with caution. patients must have: * documented hiv infection. * cd4+ cell count \>= 200 cells/mm3. 1. anticipated need for treatment with cytotoxic chemotherapeutic agents within the study time period. * treatment with immunomodulating agents. * medications that should not be administered with 141w94: terfenadine. astemizole. cisapride. triazolam. midazolam. ergotamine/dihydroergotamine-containing regimens. antiretroviral drugs. vitamin e supplements. other experimental agents. anticipated need for radiation therapy within the study time period. 1. prior protease inhibitors. * antiretroviral therapy within 2 weeks prior to entry. * treatment with cytotoxic chemotherapeutic agents within 4 weeks prior to entry. radiation therapy within 4 weeks prior to entry. current alcohol or illicit drug use that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing and protocol evaluations.

Keywords: drug therapy, combination administration, oral hiv protease inhibitors indinavir saquinavir nelfinavir vx 478
affective and physiological outcomes of virtual and mixed reality workplace exergames

Conditions: Exergame; Active Video Games (AVG); Virtual Reality; Mood Changes

Summary: the aim of this study was to compare the acute effects of virtual reality (vr) and mixed reality (mr) based exergame practices on physical and psychological health indicators during micro-breaks among university administrative staff. the main research questions aimed to be answered are: 1. how does vr exergame and mr exergame affect physical health indicators such as heart rate and perceived exertion in university administrative staff? 2. how does mr exergame with vr exergame affect the mood of university administrative staff? 3. how does mr exergame with vr exergame affect the enjoyment of exercise and gaming experience of university administrative staff? researchers will compare passive rest with vr exergame and mr exergame to see if vr and mr sessions improve physical and psychological outcomes compared to passive rest. participants will: sit quietly in a designated room for 5 minutes without engaging in any physical activity. avoid talking, using mobile devices, or interacting with others during the rest session to ensure consistent conditions for all participants.

using a randomized crossover design, participants will experience three different conditions: vr-based exergames, mr-based exergames, and passive rest. each condition will be performed on separate days, with a minimum of 48 hours between sessions to prevent carryover effects. the primary outcomes will include mood states, heart rate, and perceived exertion. these measures will help assess the immediate physical and psychological responses to the interventions. the secondary outcomes will focus on exercise enjoyment and overall gaming experience, evaluating the subjective experience and engagement levels during vr and mr exergaming sessions. the intervention will be delivered through powerbeatsvr, a rhythm-based exergame that requires physical movements such as dodging obstacles and throwing punches. vr and mr modes will be compared to determine their effectiveness in promoting physical activity and improving mood during short breaks in a workplace setting. the passive rest condition will serve as a baseline for comparison. this study addresses the growing interest in workplace wellness strategies by exploring the potential of vr and mr exergames in reducing sedentary behavior and enhancing mental well-being in work environments.

Eligibility criteria:
inclusion criteria: * 18 years and over * being suitable for physical activity according to par-q test * not exercising for 30 minutes 3 days a week * not having used vr/mr technologies before exclusion criteria: * people with epilepsy, vertigo or neurological diseases * use of antidepressants or similar medication * individuals with high physical activity level (ipaq)

Keywords: exergame active video game virtual exergame
pilot study of hematopoietic stem cell transplantation from two matched sibling donors in treating patients with poor prognosis acute leukemia and advanced lymphoproliferative malignancies

Conditions: Relapsed and Refractory Acute Leukemia

Summary: patients with active acute leukemia have dismal prognoses even with allogeneic transplantation.thus,new measures to enhance graft versus leukemia effect and reduce relapse rates are needed. relapse risk after double umbilical cord transplantations have been shown to be significantly lower compared to matched sibling and matched unrelated donor transplantations due to better graft versus leukemia effect. the investigators hypothesize, that concomitant transplantation from 2 matched siblings may improve gvl effect and reduce relapse rate in patients with high risk acute leukemias and other high risk hematological malignancies.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. patients with refractory or relapsed acute leukemia unable to receive myeloablative conditioning. 3. patients with refractory or relapsed acute leukemia able to receive myeloablative conditioning but with the following factors: aml- 2 or more of the following: duration of cr1 \< 6 months, poor cytogenetics, circulating blasts, karnofsky \< 90. all- age \> 40 or second and additional relapse, or 2 or more of the following: bm blasts \> 25%, age 18-39,first refractory relapse, donor cmv positive. 4. patients with 2 matched siblings and donor age \> 18 years old. 5. patients with advanced multiple myeloma with life expectancy of less than 6 months with standard therapy or transplantation. 6. patients with advanced lymphoma with life expectancy of less than 6 months with standard therapy or transplantation. exclusion criteria: 1. patient age \< 18 years. 2. donor age \< 18 years. 3. patients in remission or not fulfilling above disease criteria -

Keywords: acute leukemia relapse induction failure allogeneic transplantation graft versus leukemia effect
efficacy study comparing the effect of clomiphencitrate to an antagonist protocol

Conditions: Female Infertility; Ovarian Insufficiency

Summary: the aim of this study is to assess the oocyte yield of infertile women with suspected or known poor ovarian reserve (por) undergoing a gnrh antagonist protocol for ivf with merional® starting either with a low (150 iu) or a high dose (450 iu) and adding 100mg of cc (serophene®) in the early follicular phase of the stimulation (day 3 to 7). to date no rct has been conducted to compare the reproductive outcome of patients with por as defined by the eshre bologna criteria after controlled ovarian hyperstimulation with hmg in an gnrh antagonist protocol using low doses versus high doses of hmg and adding cc versus placebo. we hypothesize that adding 100 mg of cc on day 3-7 to a hmg antagonist protocol will lead to an additional increment of endogenous gt thus increasing the oocytes yield after controlled ovarian stimulation due to higher endogenous gonadotropin secretion.


Eligibility criteria:
inclusion criteria: * age: \>18 years \< 43 years * bmi: ≥ 18 ≤ 32 kg/m2 * poor responder as defined by eshre working group exclusion criteria: * age \ 43 years * pregnancy * breast feeding * uterine conditions interfering with endometrial proliferation and embryo implantation (submucous fibroids or polyps) * women diagnosed with pcos according to the rotterdam criteria * hyperprolactinaemia - untreated * both ovaries not accessible transvaginally for oocyte pick up * ovarian cysts of unclear dignity * evidence of hydrosalpinx on ultrasound * clinically significant severe systemic disease that are incompatible with pregnancy * known or suspected hypersensitivity to the active substances (gonadotrophins, ganirelix, progesterone, clomiphencitrate) * untreated thyroid or adrenal disorders * bleeding disorders * cancer * severe renal or hepatic dysfunction * necessity to take medication that could influence ovarian stimulation * history of ohss in prior ivf cycle

Keywords: female infertility poor ovarian response controlled ovarian hyperstimulation ivf antagonist protocol
adaptation among adolescents and adults with klinefelter syndrome

Conditions: Klinefelter Syndrome

Summary: this study aims to understand the impact of living with klinefelter syndrome (ks) and the factors that contribute to adaptation in adolescents and adults. individuals with ks may have variable symptoms, including hypogonadism, gynecomastia, learning disabilities, and delay and underdevelopment of secondary sexual characteristics. perhaps the most challenging symptom of ks is infertility, which seems to be a universal symptom. it is not fully understood how males with ks conceptualize their condition, cope with their diagnosis, and adapt to living with this condition. in this study, lazarus and folkman s transactional model of stress and coping provides a framework for examining coping and adaptation in males with ks. a cross-sectional research design using a quantitative survey will be utilized to examine the relationships among appraisals (illness perceptions and perceived stigma), time elapsed since learning of diagnosis, coping, and adaptation. adolescents and adults with ks will be recruited from national ks support networks via website postings, email listservs, and printed newsletter postings. adolescents will also be recruited from a private practice. participants will have the option to complete an online or paper version of the survey. the main outcome variable is adaptation to living with a ks diagnosis.

this study aims to understand the impact of living with klinefelter syndrome (ks) and the factors that contribute to adaptation in adolescents and adults. individuals with ks may have variable symptoms, including hypogonadism, gynecomastia, learning disabilities, and delay and underdevelopment of secondary sexual characteristics. perhaps the most challenging symptom of ks is infertility, which seems to be a universal symptom. it is not fully understood how males with ks conceptualize their condition, cope with their diagnosis, and adapt to living with this condition. in this study, lazarus and folkman s transactional model of stress and coping provides a framework for examining coping and adaptation in males with ks. a cross-sectional research design using a quantitative survey will be utilized to examine the relationships among appraisals (illness perceptions and perceived stigma), time elapsed since learning of diagnosis, coping, and adaptation. adolescents and adults with ks will be recruited from national ks support networks via website postings, email listservs, and printed newsletter postings. adolescents will also be recruited from a private practice. participants will have the option to complete an online or paper version of the survey. the main outcome variable is adaptation to living with a ks diagnosis.

Eligibility criteria:
* inclusion criteria: 1. must have klinefelter syndrome (47,xxy) by self-report. 2. must be 14 years or older.

Keywords: klinefelter syndrome 47,xxy xxy
influence of cpb and mini cpb to the absorption of the metoprolol

Conditions: Drug Absorption

Summary: influence of perfusion, miniperfusion and off pump coronary artery bypass grafting to the absorbtion of metoprolol postoperatively, hypothesis in that miniperfusion and off pump surgery does not decrease absorbtion of the metoprolol compared to conventional pefusion.

influence of perfusion, miniperfusion and off pump coronary artery bypass grafting to the absorbtion of metoprolol postoperatively, hypothesis in that miniperfusion and off pump surgery does not decrease absorbtion of the metoprolol compared to conventional pefusion. blood samples for concentration of metoprolol are taken preoperaively, 1. and 3. day after operation, before and 10 times after intake of 50 mg metoprolol. sudy is randomized into 3 groups: 1. miniperfusion n.15 2. perfusion n.15 3. offpump n.15

Eligibility criteria:
inclusion criteria: elective cabg patient - exclusion criteria: contraindication to metoprolol -

Keywords: metoprolol, atrial fibrillation
linezolid alone or combined with carbapenem against methicillin-resistant staphylococcus aureus (mrsa) in ventilator-associated pneumonia

Conditions: Methicillin-resistant Staphylococcus Aureus; Pneumonia, Ventilator-Associated

Summary: as previous studies showed that the synergy between linezolid and carbapenem in vitro and in vivo (animal studies), our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant staphylococcus aureus (mrsa) in ventilator-associated pneumonia (vap) patients.

linezolid is the only commercially available oxazolidinone, the first new class of antibiotic to be developed in the last three decades. although it is predominantly bacteriostatic, linezolid has good in vitro and in vivo activity against mrsa . however, several studies did not show that linezolid was superior to any of glycopeptides in treatment of mrsa pneumonia. moreover, combination therapy against mrsa is argued when several in vitro and in vivo studies showed synergy between linezolid and carbapenem or fosfomycin or rifampicin, while vancomycin and linezolid in combination should be avoided. our study is aim to investigate the activity of linezolid, alone and in combination with carbapenem against methicillin-resistant staphylococcus aureus (mrsa) in ventilator-associated pneumonia (vap) patients.

Eligibility criteria:
inclusion criteria: * pneumonia, ventilator-associated * the presence of new or persistent radiographic features * fever higher than 38°c * leukocytosis (≥11.0 ×109/l) or neutropenia (≤3.5×109/l) * purulent endotracheal * increasing oxygen requirements * endotracheal aspiration culture show methicillin-resistant s. aureus positive exclusion criteria: * immunocompromised patients (postorgan transplantation or human immunodeficiency virus-infected or neutropenic \[≤1×109/l absolute neutrophils\], or patients receiving corticosteroids \>20 mg/d for 6 months) * colonized chronically with methicillin-resistant s. aureus * pregnancy * endotracheal aspiration culture showed no mrsa

Keywords: methicillin-resistant staphylococcus aureus pneumonia, ventilator-associated linezolid imipenem/cilastatin
observational study on the management of patients with non small cell lung cancer adenocarcinoma

Conditions: Non Small Cell Lung Cancer

Summary: the main objective of the study is to determine the proportion of patients with m + mutation status among patients with non small cell lung cancer adenocarcinoma.

msd

Eligibility criteria:
inclusion criteria: * patient with lung cancer (non small cell lung cancer adenocarcinoma) * patient for whom a search for the mutational status of egfr (egfr-m +, m- or mx) has been done or is being analyzed exclusion criteria: * assessment of mutational status of egfr is not done

Keywords: m + mutation non small cell lung cancer adenocarcinoma to determine the proportion of patients with m + mutation status among patients with nsclc adenocarcinoma
the effect of case conferencing in nursing homes

Conditions: Dementia; Neurobehavioral Manifestations

Summary: this study evaluates the effect of using comprehensive geriatric assessment in combination with case conferences on the prevalence of neuropsychiatric symptoms (also known as behavioral and psychological symptoms of dementia) in norwegian nursing homes

long-term care patients in nursing homes (nh) are characterized by frailty and having multiple health problems and reduced quality of life. some of these issues relates to the quality of care and do therefore possess a potential for improvement. there is a need for approaches enabling nurses to carry out effective interventions that can promote health related to sustain or improve the nursing home patients health status. integrating a comprehensive geriatric assessment (cga) and case conferencing (cc) might be an effective method to individualize care plans in order to improve quality of care. the intervention nursing homes will implement cga, using the international resident instrument suite for long term care facilities (interrai ltcf) and cc. the patients will be included and assessed three times during a 12-month period (control and intervention nhs). in the intervention nhs the results from the cga will be reviewed in monthly ccs. the ccs are structured and consist of four main steps; evaluating the effects of earlier interventions, defining patients risks or area for improvement, defining the aetiology of the risk or problem, defining interventions and measures for improvement along with an appropriate method for evaluation. the cc group's consensus is basis for the patient's care plan.

Eligibility criteria:
inclusion criteria: * registered as long term care patient * been in the nursing home for more than a month * informed consent from the patient or legal guardians exclusion criteria: * life expectancy less than six months

Keywords: nursing homes norway
convalescent plasma to limit coronavirus associated complications

Conditions: Coronavirus

Summary: researchers are trying to assess the treatment potential and safety of anti-sars-cov-2 convalescent plasma in patients with acute respiratory symptoms with confirmed covid-19.

high titer human convalescent plasma will be extracted from apheresis donations from twenty recently-sick and currently-recovered covid-19 patients. an open-label, phase 2a clinical trial will then be conducted to administer convalescent plasma to twenty individuals with confirmed cases of covid-19 to investigate the novel application of convalescent plasma in the treatment strategy of sars-cov-2.

Eligibility criteria:
inclusion criteria: * patients must be 18 years of age or older * hospitalized with covid-19 respiratory symptoms and confirmation via covid-19 sars-cov-2 rt-pcr testing. patient is willing and able to provide written informed consent and comply with all protocol requirements. * patient agrees to storage of specimens for future testing. exclusion criteria: * female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period * receipt of pooled immunoglobulin in past 30 days * contraindication to transfusion or history of prior reactions to transfusion blood products

Keywords: 2019 novel coronavirus sars-cov-2 covid-19